In all cases, they now have gone more positive - rather than just change - it mentions reduction - which is much aggressive as chances of failure are high
From - Change from baseline to week 48 in cognition according to the Alzheimer Disease Assessment Scale-Cognition (ADAS-Cog) compared to placebo
To - Reduction in cognitive decline assessed from baseline over 48 weeks with ANAVEX2-73 compared to placebo using the Alzheimer Disease Assessment Scale-Cognition (ADAS-Cog)
2. ADCS-ADL (Activities of Daily Living) [ Time Frame: 48 weeks ]
From - Changes from baseline to week 48 in ability to perform daily activities according to the Activities of Daily Living Scale (ADCS-ADL) compared to placebo
To - Reduction in decline of the ability to perform daily activities assessed from baseline over 48 weeks with ANAVEX2-73 compared to placebo using the Activities of Daily Living Scale (ADCS-ADL)
Secondary measure
1. CDR-SB (Clinical Dementia Rating Scale Sum of Boxes) [ Time Frame: 48 weeks ]
From - change from baseline to week 48 on Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) compared to placebo
To - Reduction in cognitive decline assessed from baseline over 48 weeks with ANAVEX2-73 compared with placebo using the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)
You are very clear on what you expect & I appreciate that!
I would think Missling would at least be able to say that he is happy to expect excellent results, assuming he is confident without being hindered by the actual data to be released at CTAD.
With his close connection to the CRO, I'll bet he has some information that is worthwhile. He pays them...lol.........don't bite the finger that feeds you.
Market Data 
Markets 
AI
